Arena Pharmaceuticals (ARNA) Volatile as FDA Minutes from May 10 Panel Posted
Tweet Send to a Friend
Up)
Trader chatter on Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) is picking up after biotech watcher Adam Feuerstein of the Street.com notes that minutes from the May 10th FDA panel on lorcaserin have been posted.
He notes on Twitter, "The approved FDA panel minutes don't show lorcaserin in such a nice light. Many panelists "reluctantly voted yes..."
Investors are waiting on the 6/27 PDUFA date for drug approval.
Link to minutes and other material.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
He notes on Twitter, "The approved FDA panel minutes don't show lorcaserin in such a nice light. Many panelists "reluctantly voted yes..."
Investors are waiting on the 6/27 PDUFA date for drug approval.
Link to minutes and other material.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Fannie Mae, Freddie Mac Surge as Seriously Delinquent Rate Falls Below 3%
- UPDATE: Intuitive Surgical (ISRG) Jury Reaches Positive Verdict in Robot Case; Shares Rise
- UPDATE: Chile regulators stopped build, imposed sanctions on Barrick Gold (ABX)
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkRelated Entities
Twitter
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
